Generic Saphris Availability
SAPHRIS (asenapine maleate - tablet;sublingual)
Manufacturer: FOREST LABS INC
Approval date: August 13, 2009
Strength(s): EQ 5MG BASE, EQ 10MG BASE [RLD]
Has a generic version of Saphris been approved?
No. There is currently no therapeutically equivalent version of Saphris available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Saphris. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Sublingual or buccal pharmaceutical composition
Issued: June 9, 1998
Inventor(s): Delbressine; Leonardus Petrus Carla & Wieringa; Johannes Hubertus
Assignee(s): Akzo Noble N.V.
The invention relates to a sublingual or buccal pharmaceutical composition comprising trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz›2,3:6,7!oxepino-›4 ,5-c!pyrrole or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable auxiliaries suitable for use in sublingual or buccal compositions, and the use thereof for the manufacture of a sublingual or buccal pharmaceutical composition for the treatment of mental disorders, such as psychosis and schizophrenia.Patent expiration dates:
- June 9, 2020✓✓
- June 9, 2020
Crystal form of asenapine maleate
Issued: June 22, 2010
Inventor(s): Heeres; Gerhardus Johannes
Assignee(s): N.V. Organon
The invention relates to an orthorhombic crystal form of compound trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz [2,3:6,7]oxepino[4,5-c]pyrrole (Z)-2-butenedioate, to methods for the preparation of this crystal form and to pharmaceutical compositions comprising an orthorhombic crystal form.Patent expiration dates:
- April 6, 2026✓✓✓
- April 6, 2026
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- September 3, 2013 - ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- September 3, 2013 - MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS
- August 13, 2014 - NEW CHEMICAL ENTITY
- Saphris Consumer Information (Drugs.com)
- Saphris Consumer Information (Wolters Kluwer)
- Saphris Consumer Information (Cerner Multum)
- Saphris Black Cherry Consumer Information (Cerner Multum)
- Saphris Advanced Consumer Information (Micromedex)
- Saphris AHFS DI Monographs (ASHP)
- Asenapine Consumer Information (Wolters Kluwer)
- Asenapine Consumer Information (Cerner Multum)
- Asenapine Sublingual Advanced Consumer Information (Micromedex)
- Asenapine Maleate AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|